On April 6, 2025, ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities to address significant unmet medical needs of patients suffering from neurodegenerative conditions. Wilson Sonsini Goodrich & Rosati is advising ABL Bio on the transaction.

The Wilson Sonsini team advising ABL Bio includes Ian Edvalson, Mike Hostetler, Nguyen Pham, Katie Gu, and Matt Wheeler.

For more information, please see ABL Bio’s press release.